Seeking Alpha

Shares of CombiMatrix Corporation (CBMX) soar today, finishing up over 334% after the New...

Shares of CombiMatrix Corporation (CBMX) soar today, finishing up over 334% after the New England Journal of Medicine published two studies concluding chromonosomal microarray analysis (CMA) is superior to standard karyotyping for identifying prenatal genetic abnormalities. CBMX currently is the only publicly traded firm offering CMA diagnostics. One caveat, despite today's big run - the shares still are down over 55% from its $20 peak at the beginning of the year.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector